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Background: Cervical cancer is the third most common cancer in women worldwide, with high incidence in
lowest income countries. Vaccination against Human Papilloma Virus (HPV) may help to reduce the incidence of
cervical cancer. The aim of the study was to analyze HPV vaccination programs performance implemented in low
and middle-income countries.
Methods: The Gardasil Access Program provides HPV vaccine at no cost to help national institutions gain
experience implementing HPV vaccination. Data on vaccine delivery model, number of girls vaccinated, number of
girls completing the three-dose campaign, duration of vaccination program, community involvement and
sensitization strategies were collected from each program upon completion. Vaccine Uptake Rate (VUR) and Vaccine
Adherence between the first and third doses (VA) rate were calculated. Multivariate linear regressions analyses were
fitted.
Results: Twenty-one programs were included in 14 low and middle-income countries. Managing institutions were
non-governmental organizations (NGOs) (n = 8) or Ministries of Health (n = 13). Twelve programs were school-based,
five were health clinic-based and four utilized a mixed model. A total of 217,786 girls received a full course
of vaccination.
Mean VUR was 88.7% (SD = 10.5) and VA was 90.8% (SD = 7.3). The mean total number of girls vaccinated per
program-month was 2,426.8 (SD = 2,826.6) in school model, 335.1 (SD = 202.5) in the health clinic and 544.7
(SD = 369.2) in the mixed models (p = 0.15). Community involvement in the follow-up of girls participating in the
vaccination campaign was significantly associated with VUR. Multivariate analyses identified school-based (β = 13.35,
p = 0.001) and health clinic (β = 13.51, p = 0.03) models, NGO management (β = 14.58, p < 10−3) and duration of
program vaccination (β = −1.37, p = 0.03) as significant factors associated with VUR.
Conclusion: School and health clinic-based models appeared as predictive factors for vaccination coverage, as was
management by an NGO; program duration could play a role in the program’s effectiveness. Results suggest that
HPV vaccine campaigns tailored to meet the needs of communities can be effective. These results may be useful in
the development of national HPV vaccination policies in low and middle-income countries.
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Cervical cancer, the third most common cause of cancer
in women around the world, is a significant global health
challenge, and is the greatest cause of age-weighted years
of life lost in the developing world due its high inci-
dence [1,2]. Approximately 291 million women world-
wide are estimated to have human papillomavirus (HPV)
infection of the cervix [2]. This corresponds to an aver-
age prevalence of 10.4% for all women, although the
prevalence is higher in women younger than 25 years
(16.9%) [3]. HPV is a requirement for developing cer-
vical cancer and is found in 99.7% of cervical cancers
diagnosed worldwide [4]. Two HPV serotypes, HPV-
16 and HPV-18 are found in nearly 70% of the high-
grade cervical lesions that increase a woman’s risk for
developing cervical cancer [5].
Since 2006, two prophylactic HPV vaccines have been
available, and each has shown > 90% efficacy in prevent-
ing HPV type 16- and 18-associated high-grade cervical
lesions [6-10]. While both vaccines are being deployed
in developed countries, their use of in low and middle-
income countries has been limited due to cost and a
variety of other factors [11-15]. Recognizing that these
factors were impeding the broad use of HPV vaccin-
ation in low and middle-income countries, Merck & Co.
Inc pledged to donate Gardasil [Human Papillomavirus
Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombin-
ant] to eligible income countries through the Gardasil
Access Program (GAP). Axios Healthcare Development
is the recipient of this donation and is responsible for
managing GAP. The program was established to enable
organizations and institutions in eligible low and middle-
income countries to gain operational experience de-
signing and implementing HPV vaccination programs,
with the goal of supporting the development of successful
child and adolescent immunization models. Most vaccin-
ation programs target newborns and young children. In
addition, given the substantial morbidity and mortality as-
sociated with cervical cancer, effective strategies for its
prevention and treatment are critical for improving
women’s health throughout the developing world [14].
Pilot programs undertaken in different low and middle-
income countries support the use of universal vaccination
against HPV as an effective strategy for reducing cervical
cancer incidence in these areas [16,17].
Through the provision of vaccines at no cost, GAP
aims to foster experience in key implementation areas
that are often a challenge in lowest-income countries.
These challenges include difficulties in reaching adoles-
cent target populations, resource constraints due to
existing needs of routine vaccination campaigns, and se-
lection of optimal vaccination delivery models that most
effectively reach the eligible population with the three-
dose vaccine series [14,18]. Cultural issues, such as lackof awareness of the connection between HPV infection
and cervical cancer, reticence to discuss a sexually trans-
mitted disease, prior negative experience with other
vaccine campaigns, safety concerns, and worries about
future fertility may also create barriers to deploying HPV
vaccination effectively on a broad scale [17-28]. Con-
cerns about public health policy, such as the role of
government in deciding who should be vaccinated,
may also impact families’ willingness to have their daugh-
ters vaccinated [21].
GAP supports programs that are designed and imple-
mented by local and national institutions and organiza-
tions. The goal of this approach is to have participating
organizations and countries gain experience in the devel-
opment of relevant and effective strategies for addressing
issues that can affect coverage rates, such as infrastruc-
ture, culture, and politics. The data gathered from pro-
grams implemented under GAP reflect the experiences and
lessons learned from multiple countries and represent
diverse cultural, political, and health care environments
[18,28,29]. These data can be used to guide the develop-
ment of future national HPV vaccine campaigns in different
countries. This approach is consistent with the objectives
that the WHO’s Decade of Vaccines Collaboration Research
and Development Working Group has outlined in their
strategy to address the need for targeted implementation
research to improve both coverage of basic vaccines and
uptake of new vaccines [30].
While a number of HPV vaccination pilot programs
have been undertaken in lowest-income countries, pub-
lished results from these programs do not typically include
information related to program management. Moreover,
whereas most published studies describe results from indi-
vidual programs, GAP provides an opportunity to evaluate
a variety of HPV vaccine program types implemented in a
number of low and middle-income countries. Conse-
quently, GAP data has the potential to provide important
insight into performance factors such as vaccine delivery
model, program management and timing, community
involvement and sensitization. The aim of this study
was to analyze such factors in HPV vaccination pro-




Organizations and institutions participating in GAP
are responsible for covering all other costs associated
with their vaccination campaigns, including importation,
storage, cold chain management, distribution of vaccine,
data collection, and management of the vaccination
campaigns (i.e. community outreach and sensitization).
GAP encourages participating organizations to adhere to
WHO guidelines for HPV vaccination [30]. The WHO
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age through 13 years of age [30].
Program inclusion
For inclusion in GAP, interested organizations and insti-
tutions completed a detailed application form to de-
scribe the characteristics of their institution and their
related vaccination experience [31]. Eligible organiza-
tions and institutions included both Ministries of Health
(MoH) and local non-governmental organizations (NGOs).
The application collected information on the managing
institution (MoH or NGOs), vaccination implementa-
tion plan, estimated target population of girls, logistics,
human and financial resources available to support the
program, and health services provided by the institution
implementing the program. A standardized review form
was used to consider the applications; independent ex-
perts reviewed the applications and recommended indi-
vidual programs for inclusion. The GAP Advisory Board
reviewed the applications and expert recommendations
before issuing a recommendation for final inclusion in
GAP.
Program follow-up
Organizations and institutions participating in GAP are
required to submit final program reports once the vac-
cination program has completed administration of all
three doses of vaccine. These reports described final
program outcomes, including the number of girls vacci-
nated per round, the number of girls who received a full
course of vaccine, total number of vaccination sites and
number of girls vaccinated in each type of delivery site
(schools and/or health clinics). The reports also gathered
financial data (if available). The reports gathered infor-
mation related to community involvement actions, com-
munication key messages and methods. The program
duration was defined as the time from the date of initial
vaccine shipment through the date of delivery of the
third vaccine dose (expressed in months).
Three models of vaccine delivery were used: schools,
health clinics, and mixed models comprising both schools
and health clinic delivery sites. The primary model of vac-
cination delivery was defined according to the type of site
at which > 80% of the targeted population was vaccinated,
with mixed models defined as those using both schools
and health clinics without either site achieving 80% of tar-
get population vaccinations.
Vaccination indicators
The factors associated with program effectiveness were
assessed using two indicators: Vaccine Uptake Rate (VUR)
and Vaccine Adherence (VA). The VUR was defined as
the number of vaccinated girls that received a full-course
of vaccination (three doses) divided by the number of girlstargeted. For each program, the number of targeted girls
was determined prior to implementation using available
population, census and/or school enrollment data, among
other sources. The VA was defined as the number of girls
receiving a full course of vaccination divided by the num-
ber of girls who received a first dose. VA was calculated
between doses (D)2 and D1, D3 and D2, and D3 and D1.
Adherence between D3 and D1 (VA D3-D1) was used as a
metric of program effectiveness. In addition, the speed of
each vaccination program was estimated by calculating a
VUR per program-month (p-m), which is defined as the
number of girls completely vaccinated divided by the
number of girls targeted and multiplied by the program
duration; speed was expressed in %.Cost analyses
The cost analysis was conducted using only those pro-
grams that provided comprehensive financial data, includ-
ing staff costs. Cost data were available for seven of the 21
programs included in this study. Cost categories were not
standardized among all programs. Because GAP is a dona-
tion program, the cost of vaccine was excluded from the
total costs. Two costs measures were used: delivery cost
per dose and delivery cost per fully-immunized girl (FIG).
Cost per FIG is defined as the cost per dose multiplied by
the total number of doses delivered over three vaccination
rounds divided by the total number of girls who received
all three doses. Program costs were calculated in U.S. dol-
lars (USD).Statistical analyses
For continuous variables, data are expressed as mean
values with their standard deviation (SD) and median
(M). Student t test for parametric quantitative data and
Mann–Whitney U test for non-parametric data were
used. The Kruskal-Wallis test was used to compare VUR
and VA D3-D1 and the three vaccination delivery
models. Correlations between the number of vaccination
sites, the number of girls vaccinated by program-month,
programs duration, and VUR and VA D3-D1 were tested
using the Spearman correlation rank (rs). Two weighted
multiple linear regression analyses were fitted to deter-
mine predictive independent factors associated with
VUR and VA D3-D1. The two models were weighted on
the number of girls vaccinated per program-month. The
decision was made to use the same independent vari-
ables in the two weighted multiple linear regressions:
type of institution (MoH, NGO), vaccination delivery
model (school, health clinic and mixed), the number or
vaccination sites, and the duration of the program. A
significance level of 0.05 was used for all analyses. Statis-
tical analyses were carried out in Statview® 5.0 SAS (SAS
Institute Inc.).
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Results
A total of 21 HPV vaccination programs in 14 countries
were included. Table 1 presents the baseline characteristic
of the 21 programs. Thirteen programs (61.9%) were man-
aged by Ministry of Health, and eight programs were man-
aged by an NGO. With respect to vaccine delivery models,
12 programs were school-based, five were health clinic-
based, and four programs were mixed models (Table 1).
Of the 21 programs, seven programs began implementa-
tion in 2009 (Bhutan, Bolivia, Cambodia, Haiti, Lesotho,
Moldova and Uzbekistan); nine programs in 2010 (Bolivia
[2], Cambodia, Cameroon, Georgia, Lesotho, Nepal, Tanzania
and Uganda); four programs in 2011 (Bolivia, Honduras,
Kenya and Nepal); and one program implemented in
2012 (Honduras). Overall, mean program duration was
10.7 months (SD = 5.0, median M= 9.1). Mean duration
for programs conducted by MoH was 10.8 months (SD =
5.7, M = 7.6) and mean duration for programs conducted
by NGOs was 10.4 months (SD = 3.7, M = 9.1) (p = 0.88).
The mean VUR was 88.7% (SD = 10.5). The mean VA
between D2 and D1, D3 and D2, and D3 and D1 was
95.9% (SD = 3.9), 94.6% (SD = 5.6) and 90.8% (SD = 7.3)
respectively (Table 1).
The mean total number of girls vaccinated per program-
month (p-m) for all programs was 1,570.3 (SD = 2,336.1,
M = 523.1) (Table 1). The mean total number of girls
vaccinated per p-m by type of institution was 1,811 (SD =
2,765.1, M = 646.7) for MoH programs and 1,178 (SD =
1483.8, M = 513.0) for programs managed by NGOs
(p = 0.56). The number of girls vaccinated per p-m by
type of program is shown in Figure 1. The mean total
number of girls vaccinated per p-m was the highest in the
school model, with a mean of 2,426.8 (SD = 2,826.6), 335.1
(SD = 202.5) in mean in the health clinic models and 544.7
(SD = 369.2) in the mixed models (p = 0.15).
Table 2 summarizes the baseline characteristics and
program sensitization methods according to VUR and
VA D3-D1. As shown, programs managed by an NGO
had a higher VUR than programs managed by MoH
(96.0% vs. 87.2%, respectively, p = 0.05), whereas the in-
stitution type did not impact VA D3-D1. There was no
statistically significant difference in VUR and VA D3-D1based on the health services provided at the institution.
The type of delivery model did not have a significant im-
pact on VUR or VA D3-D1 (Table 2).
Community involvement in following-up with girls par-
ticipating in the vaccination campaign was significantly as-
sociated with mean VUR, 95.4% (SD = 9.4) versus 86.1%
(SD = 10.8) for communities with and without involve-
ment, respectively (p = 0.05) (Table 2). Although VUR
increased with the number of community involvement ac-
tions, the difference remained insignificant (Table 2).
Mean VUR for programs with and without key messages
about the safety and efficacy of the vaccine was 93.3% (SD=
9.1) and 83.6% (SD = 10.8), respectively (p = 0.05).
Overall, the mean VUR per p-m was 7.53% (SD = 0.88,
M = 7.54). The mean VUR p-m did not differ signifi-
cantly among the different delivery models: schools
(7.73%, SD = 0.78), health clinics (7.48%, SD = 1.13), and
mixed models (6.99%, SD = 0.80) (p = 0.35). There was a
significant correlation between the VUR p-m and the VA
D3-D1 (rs = 0.66, p < 10
−4), as well as between the total
number of girls vaccinated per p-m and the number of
vaccination sites (rs = 0.57, p = 0.007). When the correla-
tions were stratified on vaccine delivery models, the three
correlations remained positive: health clinic (rs = 0.65, p =
0.27), school (rs = 0.18, p = 0.66), and mixed (rs = 0.72, p =
0.03). There was a negative correlation between the vac-
cination program duration and VUR (rs = −0.27, p = 0.23),
and a significantly negative correlation between duration
and VA D1-D3 (rs = −0.48, p = 0.03).
The first weighted multiple linear regression model
identified program management by an NGO (p < 10−3),
school and health clinic delivery model, and duration of
the program as significantly independent predictors of
VUR (Table 3). In the second weighted multiple linear
regression model, no significant association was found
between VA D3-D1 and the independent variables fitted
in the model, and program duration was the only inde-
pendent variable that approached statistical significance
(p = 0.07) (Table 3).
Although comprehensive cost data were not proactively
collected from programs participating in GAP, these data
were available for seven programs. The mean cost per FIG
was USD 8.75 (SD = 4.31, M = 7.10, range = 5.00–17.26)
(Table 4). For five programs, the mean cost ranged
from USD 5.0 to 7.23, while the two programs with the
lowest target populations had substantially higher costs
per FIG (USD 11.73 and 17.26). Mean cost per vaccine
dose was USD 2.74 (SD = 1.35, M = 2.34, range = 1.38–
5.39) (Table 4). There was no significant difference in cost
per FIG or per vaccine dose among the three vaccine de-
livery models, and the cost per FIG was similar in each of
the three school-based models included in the analysis
(USD 7.02 in Moldova, 7.12 in Lesotho, and 7.23 in Nepal)
(data not shown).


















Adherence to vaccination %
D2-D1 D3-D2 D3-D1
Bhutan MoH School 3,200 2,721 21 686.1 85.0 96.8 91.3 88.3
Bolivia 1 NGO School 3,480 3,739 69 732.2 107.4 99.5 96.6 96.2
Bolivia 2 MoH Mixed 7,500 5,513 19 386.1 73.5 91.6 90.4 82.9
Bolivia 3 NGO School 30,900 27,597 594 4,039.7 89.3 98.1 98.0 96.2
Bolivia 4 MoH School 50,000 44,037 2,142 9,650.9 88.1 91.6 95.1 87.1
Cambodia 1 MoH Mixed 9,600 7,464 10 1,096.2 77.8 91.9 95.5 87.7
Cambodia 2 MoH Health clinic 2,000 2,027 1 1,096.2 101.4 98.2 97.0 95.3
Cameroon NGO Mixed 6,400 5,796 87 348.9 90.6 95.2 88.9 84.7
Georgia MoH Health clinic 6,400 4,420 28 502.9 69.1 88.7 102.0 90.4
Haiti NGO School 3,300 2,884 162 333.6 87.4 86.8 87.3 75.8
Honduras 1 MoH School 3,200 3,164 298 523.1 98.9 99.6 98.9 98.5
Honduras 2 NGO Mixed 1,575 1,472 25 332.5 93.5 99.3 88.9 88.3
Kenya MoH Health clinic 3,000 2,500 1 193.3 83.3 95.7 78.1 74.7
Lesotho 1 MoH School 40,000 33,818 172 257.8 92.6 96.8 95.8 92.7
Lesotho 2 MoH School 40,100 37,051 436 4,809.6 84.3 94.9 98.5 93.4
Moldova MoH School 6,934 6,903 87 3,844.7 99.6 99.9 100 99.9
Nepal 1 NGO School 3,000 3,164 54 714.6 105.5 99.7 99 98.7
Nepal 2 NGO School 10,000 9,918 216 351.7 99.2 99.5 99.3 98.8
Tanzania MoH School 5,532 4,211 176 2,994.6 76.1 96.1 93.5 89.9
Uganda NGO Health clinic 985 937 10 442.2 95.1 94.3 93.5 88.1
Uzbekistan MoH Health clinic 8,450 8,450 51 88.6 100.0 100 100 100
Total mean (SD, M) - - 245,556 217,786 4,659 1,570.3 (2,336.1, 523.1) 88.7 (10.5, 89.5) 95.9 (3.9, 96.8) 94.6 (5.6, 95.7) 90.8 (7.3, 90.4)



















Figure 1 Mean total number of girls vaccinated per
program-month (p-m) by vaccine delivery model, Gardasil
Access Program, 2009–2013 (N = 21 programs).
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This study provides insight into factors that impact the
outcome of HPV vaccine campaigns in lowest-income
countries. Among the key findings of this study are: first,
high VUR (mean VUR = 88.7%), and VA D3-D1 (mean
VA = 90.8%) were found across the 21 programs
assessed; second, school-based vaccine delivery models
and program management by an NGO each had a posi-
tive and statistically significant impact on VUR; third,
duration of the vaccination campaign appears also as a
predictive factor for VUR and VA, with increased speed
of vaccination predicting higher VUR and VA.
Program management by NGOs was significantly asso-
ciated with VUR. NGOs are typically smaller and face
fewer internal bureaucratic hurdles than a Ministry of
Health. Consequently, the finding that NGO manage-
ment of a program could predict better VUR compared
with MoH management may be related to the relative
speed with which each type of organization can im-
plement and execute a program, rather than reflecting
overall capabilities or competencies of either type of
institution. It should also be noted that programs im-
plemented by NGOs have benefited from the authorization
and the support of the national health authorities of
the country.
Our results found also that program duration is a sig-
nificant predictor of VUR (p = 0.03) and shows an asso-
ciation with VA (p = 0.07). Shorter duration predicted
improved vaccination indicators, suggesting that a longer
interval between vaccine shipment and initiation of the
third vaccine dose reflects difficulty in vaccinating girls
against HPV in a timely manner. A lack of momentum
within a given program may lead to loss of interest in
completing all three doses of vaccine among girls and
their parents. Similarly, a delay in completing all threedoses of vaccine may reflect logistical difficulties related
to vaccine supplies or personnel. While speed of vaccin-
ation has not typically been included in standard efficacy
metrics for vaccine programs, these data could suggest
that it could be as an aggregate indicator of a well-run
program. This result should be confirmed in further
studies, and we hope that other investigators will include
speed of vaccination in their future studies in order to
determine if this metric is a reproducible and reliable
predictive factor for program performance. It should be
noted that specific program duration was not a require-
ment imposed on Program grantees by the GAP.
Of the three types of vaccine delivery models assessed
in this study, the school-based model was found to be
the strongest positive predictive factor of higher VUR.
School-based programs likely have the strongest impact
on VUR; daily attendance of target girls at school allows
them to be vaccinated more quickly than might occur at
a health clinic that requires the girl to make a special
trip. Given that this finding is based on data from a rela-
tively large number of programs, we believe that this re-
sult supports the use of school-based models as a way to
optimize delivery of HPV vaccines to school-aged girls.
School-based delivery models may be more effective at
delivering HPV vaccine because girls between the ages
of 9 and 13 years, the target population recommended
by the WHO for HPV vaccination, are likely to be
present at school in the 12 programs.
The association between school-based models and in-
creased VUR is supported by other studies that demon-
strate the relevance of such models in delivering HPV
vaccine. A high rate of HPV vaccine coverage (93.2%
after three doses) was achieved in Rwanda using a school
model [32]. One study found that school-based models
have also been effective in demonstration programs in
Peru, Uganda, Viet Nam, and India (vaccine coverage
ranged from 82.6% to 96.1%) [17], That report suggests
that schools may be especially well-suited to reaching
girls in the targeted HPV vaccine age range [32]. Add-
itional studies also support the effectiveness of school-
based HPV vaccine delivery programs in developing
countries [33]. Similarly, a study in Brazil found VURs
of 87.5%, 86.3%, and 85.0% at D1, D2 and D3 time re-
spectively, in school-based vaccination delivery programs
[34]. In that study, no significant differences in VUR
were observed between public and private schools or
urban and rural schools [34].
Other studies indicate that school-based models may
be more effective than age-based models [32,33,35].
With 84% of children in developing world attending pri-
mary school in 2006, school-based models should be
considered as an effective method for delivering HPV
vaccine to target populations [36]. However, as previously
reported, school-based programs may face obstacles if
Table 2 Baseline program characteristics and sensitisation methods of programs according to vaccine uptake rate
(VUR) and D3-D1 adherence to HPV-vaccination, Gardasil Access Program, 2009–2013 (N = 21 programs)
Mean VUR (SD) % p Mean D3-D1* adherence to vaccination (SD) % p
Managing institution
MoH (n = 13) 87.2 (10.7) 0.05 90.8 (7.1) 0.99
NGO (n = 8) 96.0 (7.4) 90.8 (8.1)
Institution services Cancer management
Presence (n = 14) 91.6 (11.3) 0.51 91.7 (7.8) 0.43
Absence (n = 7) 88.4 (8.5) 89.0 (6.5)
Health care services
Presence (n = 16) 89.8 (10.6) 0.56 90.2 (7.8) 0.51
Absence (n = 5) 93.0 (10.3) 92.8 (5.5)
Vaccination services
Presence (n = 20) 91.1 (10.3) 0.25 90.9 (77.5) 0.87
Absence (n = 1) 80.2 (−) 89.9 (−)
Vaccination delivery model
HC (n = 5) 89.8 (13.6) 90.1 (9.5)
Schools (n = 12) 93.1 (8.8) 0.30 92.5 (7.3) 0.52
Mixed (n = 4) 83.8 (9.7) 87.9 (5.1)
Community involvement actions
Communication key messages definition
Yes (n = 11) 94.1 (11.4) 0.27 92.5 (7.5) 0.29
No (n = 10) 88.8 (9.2) 89.0 (7.0)
Girls follow-up
Yes (n = 13) 95.4 (9.4) 0.05 91.4 (7.5) 0.67
No (n = 8) 86.1 (10.8) 89.9 (7.4)
Vaccination sessions announcement
Yes (n = 11) 93.0 (9.4) 0.28 89.3 (9.2) 0.35
No (n = 10) 88.8 (11.5) 92.4 (4.3)
Girls recruitment
Yes (n = 14) 89.3 (10.7) 0.44 90.3 (8.3) 0.62
No (n = 7) 93.1 (9.9) 92.0 (5.3)
Number of community involvements actions
0 (n = 3) 88.0 (12.1) 90.4 (4.2)
1-2 (n = 7) 85.7 (10.0) 0.20 89.1 (7.6) 0.72
3-4 (n = 11) 94.4 (9.5) 92.1 (8.0)
At least one community involvement action
0 (n = 3) 88.0 (12.1) 0.56 90.4 (4.2) 0.92
> = 1 (n = 18) 92.0 (10.7) 90.9 (7.8)
Communication key messages and methods
Vaccine administration modalities
Yes (n = 13) 89.4 (10.2) 0.65 90.3 (8.2) 0.70
No (n = 8) 92.4 (10.2) 91.6 (6.0)
Vaccine safety and efficacy
Yes (n = 15) 93.3 (9.1) 0.05 92.3 (6.9) 0.15
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Table 2 Baseline program characteristics and sensitisation methods of programs according to vaccine uptake rate
(VUR) and D3-D1 adherence to HPV-vaccination, Gardasil Access Program, 2009–2013 (N = 21 programs) (Continued)
No (n = 6) 83.6 (10.8) 87.2 (7.6)
HPV and link to cancer
Yes (n = 15) 88.4 (10.3) 0.13 88.8 (7.3) 0.04
No (n = 6) 95.9 (8.9) 95.9 (4.6)
MoH: Ministry of Health. NGO: non-governmental organization.
*Vaccine adherence between the third and the first dose.
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and/or door-to-door follow up may be required in order
to complete the three-dose vaccine series [31]. Within the
scope of GAP, girls moving away during school breaks
or between school years were reported as a key factor
that increased the number of girls lost to follow-up.
In order to address this issue, it is important that the
full vaccination course is administered during the aca-
demic school year. This again advocates for the need to
carefully monitor the duration of the campaign and to en-
sure that girls receive all three doses within the recom-
mended vaccine administration schedule that runs for a
period of six months. We should also note that while an
earlier analysis of only 8 programs participating in GAP
found that mixed models were more effective than school-
based models, the current analysis contains a larger num-
ber of programs, includes a higher number of vaccinated
girls, and also utilizes more sophisticated statistical ana-
lyses [31].
Community involvement actions appeared to impact the
efficacy of the programs, especially the VUR [32]. Pro-
grams in which communities were engaged in following-
up with girls participating in the vaccination campaign
had a higher mean VUR compared with programs that
did not engage the community in this activity. This action
had no effect on VA, suggesting that enrollment in the
vaccine campaign is a bigger hurdle than getting girls whoTable 3 Weighted multiple linear regressions* analysis of pre






Number of sites of vaccination 0.01




*Weighted on the number of girls vaccinated by program-month.
MoH: Ministry of Health. NGO: Non-Governmental Organization.have enrolled to complete the three vaccine doses. There
was an interesting trend toward increased VUR with
an increase in the number of community involvement
actions, suggesting a dose-effect response. However, this
trend did not reach statistical significance, which may in-
dicate that the type of activity in which communities are
involved may be more important than the overall level of
community engagement.
Understanding which aspects of an HPV vaccine cam-
paign are most influenced by community standards,
morals, and expectations may help in developing com-
munity engagement actions that impact VUR and VA
[29]. Community sensitization about the availability and
value of vaccinating school-aged girls against HPV may
impact vaccine uptake. A study in Brazil found that the
method used initially to notify parents about the vaccine
had a significant impact on vaccine indicators [34]. That
study found that information disseminated by schools
was more important than information provided by local
media with respect to vaccine uptake [34].
The inclusion of key messages regarding the safety and
efficacy of the vaccine had a positive impact on VUR.
This finding again suggests that initial enrollment is a
greater barrier to completing the three doses of vaccine
than is the need to return for repeated vaccine adminis-
trations. Key messages that address safety and efficacy at
the launch of a vaccine campaign may help to increasedictive factors of HPV-vaccination uptake rate (VUR) and
2009–2013 (N = 21 programs)
uptake rate D3-D1 vaccination adherence
ient 95% CI p β coefficient 95% CI p
Ref
7.64 to 21.52 < 10−3 3.90 −2.98 to 10.78 0.24
−0.009 to 0.34 0.23 0.009 −0.01 to 0.03 0.41
−2.22 to −0.62 0.03 −1.01 −1.98 to 0.45 0.07
Ref
1.46 to 25.57 0.03 3.68 −8.28 to15.63 0.66
6.10 to 20.61 0.001 3.00 −4.20 to 10.20 0.89
Table 4 Cost analysis* (in US$) in seven programs included in Gardasil Access Program, 2009–2013 (N = 7 programs)
Vaccine delivery model Total costs Cost per FIG Cost per vaccine dose
Cambodia 1 Mixed 44,157 5.91 1.86
Honduras 2 Mixed 17,269 11.73 3.60
Kenya Health clinic 12,500 5.00 1.38
Lesotho 2 School 263,815 7.12 2.28
Moldova School 48,478 7.02 2.34
Nepal 2 School 71,677 7.23 2.39
Uganda Health Clinic 16,175 17.26 5.39
Total mean (SD, M) - 474,071 8.75 (4.31, 7.10) 2.74 (1.35, 2.34)
FIG: Fully-immunized Girl.
*Includes staffing costs; excludes vaccine costs.
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http://www.biomedcentral.com/1471-2458/14/670enrollment by easing safety concerns and educating girls
and their parents about the potential benefits of protec-
tion against the long-term consequences of HPV infec-
tion. The relatively high rate of VA D3-D1 (90.8%) found
in the 21 programs suggests that most girls who partici-
pate in the first dose of the campaign remain in the pro-
gram and complete the vaccine series. These results are
consistent with those of a study conducted in Brazil, which
found a 97.2% three-dose adherence rate in a school-based
HPV vaccine delivery model [34]. This finding is important
for those countries interested in implementing an HPV vac-
cination program to consider [26,34]. Given the availability
of census data from the Ministry of Education, and the high
density of targeted girls within school populations, school-
based delivery models appear to be the optimum approach
for reaching girls eligible for vaccination against HPV
[33]. Significant effort should be made at the start of any
HPV vaccine program to identify all eligible girls and de-
termine the most effective way to include them in the vac-
cine campaign.
For low and middle-income countries, it is a challenge
to conduct effective cost analyses around HPV vaccin-
ation. Many countries adapt existing cost models, but
these have been developed for high-income countries
and may not be relevant [37]. Model predictions using
six different vaccination models suggest that vaccination
can reduce the incidence of HPV infection and cervical
cancer in a cost-effective manner [38]. In these models,
factors that influence cost effectiveness are discount rate,
duration of vaccine protection, vaccine price, and HPV
prevalence. In an effort to provide relevant data that could
be used in designing HPV vaccine programs for low- and
middle-income countries, we gathered cost data for seven
of the GAP programs.
The mean cost per FIG and vaccine dose across the
seven programs was estimated to be USD 8.80 and USD
2.70, respectively. Due to the small number programs
with cost data available for this study, it was not possible
to detect a significant difference in cost per FIG or per
vaccine dose among the three models of vaccine deliveryin this analysis. However, a study conducted in Tanzania
found that the cost per FIG was lower for class-based
delivery models compared with age-based delivery in a
large schools-based delivery programs including a total
of 134 primary schools [39]. Another study in Tanzania
found that implementation of a nationwide HPV vaccine
program was associated with significant non-vaccine costs,
such as financing of pre-introduction activities, develop-
ment of new delivery infrastructure, and the deployment of
new human resources or reallocation of existing personnel
[40]. A study that was conducted in Peru, Uganda and Viet
Nam and included five HPV vaccination projects found
that the cost per vaccine was lower when vaccine delivery
was integrated into health services compared with school-
based and integrated outreach [41]. Given the importance
of building and enhancing the infrastructure for delivering
health care to pre-adolescents, investments in non-vaccine
costs related to HPV vaccination campaigns could be am-
ortized over a broader array of health services that deliver
a variety of interventions to the HPV vaccine target popu-
lation [33,41].
While our cost data include staffing costs for the pro-
grams assessed, they do not provide more detailed infor-
mation on other non-vaccine costs categories that could
substantively impact the implementation or sustainabil-
ity of the programs [42]. A review of the available data
from low- and middle-income countries found that HPV
vaccination is cost-effective and potentially cost saving,
especially in settings without organized cervical screen-
ing programs [43].
Our study has several limitations. First, the 21 pro-
grams used various sources of census data that may have
been potentially inaccurate to calculate their target pop-
ulations, which could impact VUR results. Our finding
of VUR greater than 100% in three programs may indi-
cate an under-estimation of the target population and/or
recruitment of girls from outside of the original target
area, suggesting that the methodologies used for deter-
mining the target population may be suboptimal. Sec-
ond, because 21 programs were included in the study, a
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particularly for the analysis between the sensitization
methods used in different programs and VUR and VA
results. Consequently, the results from a given model
may not accurately reflect the potential performance of
that model over an entire population and larger vaccin-
ation programs. Third, we have defined program dur-
ation as the time from the date of shipment of first
vaccine dose to the date of delivery of the third vaccine
dose. Although this may not be the most precise meas-
urement of program duration, the definition that we
used yielded interesting results and warrants further
evaluation. Despite these limitations, this study provides
important insight into factors that impact VUR and VA
in a very large sample of HPV vaccine programs reach-
ing more than 217,000 girls within a broad range of low
and middle-income country contexts.
Conclusions
The high VUR and VA results across the 21 programs
assessed in this study are consistent with previously re-
ported studies from a variety of other HPV vaccine pilot
programs [31,32,34,44-47]. A school-based model ap-
peared to be a predictive factor for vaccination coverage,
as was management by an NGO. Taken together, these
findings suggest that there may not be a “gold standard”
vaccination program applicable on a global or even na-
tional scale. Rather, tailoring vaccine campaigns to meet
the needs, challenges, and cultural priorities of specific re-
gions or communities appears to generate programs with
a high rate of success as determined by VUR and VA [48].
The diverse HPV vaccine programs included in this study
provide concrete examples of how such programs can be
adapted to address local and regional issues and concerns,
and provide a useful framework in which countries can
consider how to best expand their own HPV vaccination
programs based on their individual epidemiological,
economic, and health system challenges. The programs
included in this study may be used as a starting point for
national-scale HPV vaccination programs in their respect-
ive countries and related results may also be useful in the
development of national HPV vaccination policies in low
and middle-income countries.
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